Analysis suppression is a distinct decrease in a person's overall ability to process information and logically or creatively analyze concepts, ideas, and scenarios. The experience of this effect leads to significant difficulty contemplating or understanding basic ideas in a manner which can temporarily prevent normal cognitive functioning.
Analysis suppression is often accompanied by other coinciding effects such as sedation, thought deceleration, and emotion suppression. It is most commonly induced under the influence of heavy dosages of antipsychotic compounds, and is associated with long term use of such drugs like quetiapine, haloperidol, and risperidone. However, it can also occur in a less consistent form under the influence of heavy dosages of dissociatives, cannabinoids, and GABAergic depressants.
Compounds within our psychoactive substance index which may cause this effect include:
- Responsible use
- Subjective effects index
- Psychedelics - Subjective effects
- Dissociatives - Subjective effects
- Deliriants - Subjective effects
- Knowles, E. E., David, A. S., & Reichenberg, A. (2010). Processing speed deficits in schizophrenia: reexamining the evidence. American Journal of Psychiatry, 167(7), 828-835. https://doi.org/10.1176/appi.ajp.2010.09070937
- Takeuchi, H., Suzuki, T., Remington, G., Bies, R. R., Abe, T., Graff-Guerrero, A., ... & Uchida, H. (2013). Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study. Schizophrenia bulletin, 39(5), 993-998. https://dx.doi.org/10.1093%2Fschbul%2Fsbt090
- Fried, P. A., Watkinson, B., & Gray, R. (2005). Neurocognitive consequences of marihuana—a comparison with pre-drug performance. Neurotoxicology and teratology, 27(2), 231-239. https://doi.org/10.1016/j.ntt.2004.11.003
- Kawai, N., Yamakawa, Y., Baba, A., Nemoto, K., Tachikawa, H., Hori, T., ... & Iidaka, T. (2006). High-dose of multiple antipsychotics and cognitive function in schizophrenia: the effect of dose-reduction. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 30(6), 1009-1014. https://doi.org/10.1016/j.pnpbp.2006.03.013
- Husa, A. P., Moilanen, J., Murray, G. K., Marttila, R., Haapea, M., Rannikko, I., ... & Koponen, H. (2017). Lifetime antipsychotic medication and cognitive performance in schizophrenia at age 43 years in a general population birth cohort. Psychiatry research, 247, 130-138. https://dx.doi.org/10.1016%2Fj.psychres.2016.10.085
- Paraherakis, A., Charney, D. A., & Gill, K. (2001). Neuropsychological functioning in substance-dependent patients. Substance use & misuse, 36(3), 257-271. https://doi.org/10.1081/JA-100102625